Literature DB >> 15463411

The endemic normal in lymphatic filariasis: A static concept.

K P Day1.   

Abstract

Residents of areas endemic for lymphatic filariasis are continually exposed to infection with mosquito-transmitted infective larvae (L3), some of which survive to become adult worms and subsequently produce micro filarial (mf) transmission stages. The question of whether naturally acquired resistance occurs in adult residents of endemic areas has recently become of interest as the development of molecular vaccines against filarial parasites is being considered(1,2). There have been two epidemiological approaches to demonstrate acquired resistance to Filariasis in human populations. In this review Karen Day examines both approaches in the context of an immunoepidemiological study of bancroftian filariasis in Papua New Guinea (PNG). The merits of each as a conceptual framework for studies of protective immunity in lymphatic filariasis will be discussed.

Entities:  

Year:  1991        PMID: 15463411     DOI: 10.1016/0169-4758(91)90215-a

Source DB:  PubMed          Journal:  Parasitol Today        ISSN: 0169-4758


  9 in total

1.  The abundant larval transcript-1 and -2 genes of Brugia malayi encode stage-specific candidate vaccine antigens for filariasis.

Authors:  W F Gregory; A K Atmadja; J E Allen; R M Maizels
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

2.  Improving the efficacy of a prophylactic vaccine formulation against lymphatic filariasis.

Authors:  Nikhil Chauhan; Priyankana Banerjee; Vishal K Khatri; Andrew Canciamille; Jessica Gilles; Ramaswamy Kalyanasundaram
Journal:  Parasitol Res       Date:  2017-08-21       Impact factor: 2.289

3.  Th1-like antifilarial immune responses predominate in antigen-negative persons.

Authors:  K A Dimock; M L Eberhard; P J Lammie
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

4.  Multivalent fusion protein vaccine for lymphatic filariasis.

Authors:  Gajalakshmi Dakshinamoorthy; Abhilash Kumble Samykutty; Gnanasekar Munirathinam; Maryada Venkatarami Reddy; Ramaswamy Kalyanasundaram
Journal:  Vaccine       Date:  2012-10-02       Impact factor: 3.641

5.  Ivermectin-facilitated immunity in onchocerciasis; activation of parasite-specific Th1-type responses with subclinical Onchocerca volvulus infection.

Authors:  P T Soboslay; C G Lüder; W H Hoffmann; I Michaelis; G Helling; C Heuschkel; C M Dreweck; C H Blanke; S Pritze; M Banla
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

6.  Differential antibody isotype reactivity to specific antigens in human lymphatic filariasis: gp15/400 preferentially induces immunoglobulin E (IgE), IgG4, and IgG2.

Authors:  M Yazdanbakhsh; W A Paxton; A Brandenburg; R Van Ree; M Lens; F Partono; R M Maizels; M E Selkirk
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

7.  Host protective immunity and vaccine development studies in lymphatic filariasis.

Authors:  M V Reddy; R Alli; B C Harinath
Journal:  Indian J Clin Biochem       Date:  2000-08

8.  Single multivalent vaccination boosted by trickle larval infection confers protection against experimental lymphatic filariasis.

Authors:  S K Joseph; K Ramaswamy
Journal:  Vaccine       Date:  2013-06-02       Impact factor: 3.641

9.  Evaluation of a multivalent vaccine against lymphatic filariasis in rhesus macaque model.

Authors:  Gajalakshmi Dakshinamoorthy; Agneta von Gegerfelt; Hanne Andersen; Mark Lewis; Ramaswamy Kalyanasundaram
Journal:  PLoS One       Date:  2014-11-17       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.